STOCK TITAN

Suvretta Capital and Averill report sizable Biohaven (BHVN) stakes in 13G/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Suvretta Capital Management and affiliates reported significant ownership stakes in Biohaven Ltd. common shares as of 12/31/2025. Suvretta Capital Management, LLC and its principal, Aaron Cowen, each beneficially own 10,286,937 common shares, representing 7.8% of the class, with shared voting and dispositive power over these shares.

Averill Master Fund, Ltd., an advisory client of Suvretta, directly owns 8,800,438 common shares, equal to 6.6% of the class, also with shared voting and dispositive power. All securities in this amendment are directly owned by Suvretta advisory clients, and the reporting persons state that the holdings are not for the purpose of changing or influencing control of Biohaven.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



SUVRETTA CAPITAL MANAGEMENT, LLC
Signature:By: /s/ Andrew Nathanson
Name/Title:Andrew Nathanson, General Counsel and Chief Compliance Officer
Date:02/13/2026
AVERILL MASTER FUND, LTD.
Signature:By: /s/ Andrew Nathanson
Name/Title:Andrew Nathanson, Authorized Signatory
Date:02/13/2026
AARON COWEN
Signature:By: /s/ Aaron Cowen
Name/Title:Aaron Cowen
Date:02/13/2026

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Exhibit Information

[Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification]

FAQ

What stake in Biohaven Ltd. (BHVN) does Suvretta Capital report?

Suvretta Capital Management, LLC reports beneficial ownership of 10,286,937 Biohaven common shares, representing 7.8% of the class as of 12/31/2025. Suvretta has shared voting and dispositive power over all these shares, held through its advisory clients.

How many Biohaven (BHVN) shares does Averill Master Fund, Ltd. own?

Averill Master Fund, Ltd. directly owns 8,800,438 Biohaven common shares, representing 6.6% of the class. It has shared voting and dispositive power over all of these shares, and is identified as an advisory client of Suvretta Capital Management, LLC in the filing.

What is Aaron Cowen’s reported ownership in Biohaven (BHVN)?

Aaron Cowen is reported as beneficially owning 10,286,937 Biohaven common shares, equal to 7.8% of the class. He has shared voting and dispositive power over these shares, which are held by advisory clients of Suvretta Capital Management, LLC, where he is the control person.

Are Suvretta and its clients seeking control of Biohaven (BHVN)?

The reporting persons certify that Biohaven securities were not acquired and are not held for the purpose of changing or influencing control of the issuer. They also state the holdings are not in connection with any transaction having that control-related purpose or effect.

Who actually owns the Biohaven (BHVN) shares reported in this Schedule 13G/A?

All securities in this Amendment No. 3 are directly owned by advisory clients of Suvretta Capital Management, LLC. Except for Averill Master Fund, Ltd., none of these advisory clients is stated to beneficially own more than 5% of Biohaven’s common shares.

Do the reporting persons claim full beneficial ownership of their Biohaven (BHVN) holdings?

Each reporting person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest. The statement clarifies it should not be deemed an admission of beneficial ownership for Section 16 or any other legal purpose.
Biohaven

NYSE:BHVN

BHVN Rankings

BHVN Latest News

BHVN Latest SEC Filings

BHVN Stock Data

1.53B
120.40M
11.55%
82.71%
10.06%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN